Coave Therapeutics lève €32 millions d'euros en série A pour accélérer le développement de ses médicaments génétiques de nouvelle génération Le tour de table a été mené par Novo Holdings A/S et Bpifrance (dans le cadre de la stratégie d'investissement InnoBio), avec la participation d'investisseurs américains et européens, Invus et UI...

Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicines Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US and EU investors Invus and UI Investissement alongside existing...

Coave Therapeutics appoints Leading World Experts to newly formed Scientific Advisory Board dedicated to its Genetic Medicine Delivery Platform Paris, France, October 12th, 2023– Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces the formation of its new Scientific Advisory Board...

Registration Now Open for 2024 MDA Clinical & Scientific Conference, to Showcase Cutting Edge Research Advancements and Clinical Achievements in Neuromuscular Disease New York, Aug. 09, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), convener of the largest worldwide gathering of the neuromuscular disease community, announced today that...